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BACKGROUND: Infant leukaemia is likely initiated in utero.
METHODS: We examined whether analgesic use during pregnancy was associated with risk by completing telephone interviews of the
mothers of 441 infant leukaemia cases and 323 frequency-matched controls, using unconditional logistic regression.
RESULTS: With the exception of a reduced risk for infant acute myeloid leukaemias with non-aspirin non-steroidal anti-inflammatory
drugs (NSAID) use early in pregnancy (odds ratios¼0.60; confidence intervals: 0.37–0.97), no statistically significant associations
were observed for aspirin, non-aspirin NSAIDs, or acetaminophen use in early pregnancy or after knowledge of pregnancy.
CONCLUSION: Overall, analgesic use during pregnancy was not significantly associated with the risk of infant leukaemia.
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Infant leukaemia, diagnosed in the first year of life, is rare, with an
incidence rate of 39.9 per million in the United States (Linabery
and Ross, 2008). Approximately 60% of infant acute myeloid
leukaemias (AML) and 80% of infant acute lymphoblastic
leukaemias (ALL) involve rearrangement of the MLL gene (Ross
and Spector, 2006), which are rare in older children and adults.
Evidence of an in utero origin for some infant leukaemia comes
from molecular studies, in which MLL translocations identified in
leukaemia cells at diagnosis were also found in Guthrie cards
collected shortly after birth (Gale et al, 1997; Greaves and Wiemels,
2003). Further, studies of twins with leukaemia revealed the
presence of identical MLL rearrangements, suggesting that
the initiating event occurs in utero in one twin and is transferred
to the other twin via shared placental circulation (Greaves et al,
2003). The only firmly established risk factors for childhood
leukaemia are in utero exposure to X-rays, specific genetic
syndromes, such as Down’s syndrome, and high birth weight
(reviewed in Ross and Spector (2006)), which together explain only
a very small proportion of leukaemia cases.
Regular use of aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs) has been associated with a reduced risk of many
adult cancers (Gonzalez-Perez et al, 2003; Bosetti et al, 2006;
Elwood et al, 2009). Two studies of adult leukaemia suggested a
protective effect with aspirin (Kasum et al, 2003; Weiss et al, 2006),
but no effect with non-aspirin NSAIDs, and a possible increased
risk with acetaminophen (Weiss et al, 2006). For childhood
leukaemia, results are inconsistent with regard to maternal
analgesic use (Wen et al, 2002; Shaw et al, 2004; Schuz et al,
2007), although many of these drugs are known to cross the
placenta (Alano et al, 2001).
Given the paucity of risk factors identified for infant leukaemia,
the strong evidence of an in utero origin, and the potential
for possible effects on the developing fetus, we examined non-
prescription maternal analgesic use and the risk of infant
leukaemia.
MATERIALS AND METHODS
Details for recruitment and data collection have been reported
previously (Spector et al, 2005; Puumala et al, 2009, 2010). Cases
comprised infants diagnosed with or treated for ALL or AML in the
first year of life at one of the Children’s Oncology Group (COG)
institutions in the United States or Canada between January 1996
and October 2002 (phase I) and January 2003 and December 2006
(phase II). Additional eligibility criteria included the availability of
a Spanish-speaking (phase II only) or English-speaking biological
mother for telephone interview, and the absence of Down’s
syndrome. During phase I of recruitment, 348 cases were
confirmed as eligible and interviews were completed for 240
(69%). For phase II, 345 potentially eligible cases were identified
and 203 (59%) completed interviews.
During phase I of recruitment, controls were identified using
random digit dialling, and frequency matched to cases on year of
birth. Interviews were completed for 254 of 430 potentially eligible
controls (59% field response rate). In phase II, controls were
identified through a sample of state birth registries. Controls were
frequency matched to cases on year of birth and region of
residence based on the distribution of cases enrolled during phase I.
Interviews were completed for 71 out of 267 potentially eligible
controls (27% field response rate). The two control groups were
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characteristics (Puumala et al, 2009), and thus were combined
into one control group for this analysis.
Informed consent was obtained from all participants. Informa-
tion on maternal and infant characteristics was collected through
computer-assisted telephone interviews with the biological mother.
Analgesic questions included maternal use of aspirin, acetamino-
phen and non-aspirin NSAIDs, both before and after knowledge
of pregnancy, including the frequency of use during these two time
periods. The frequency of use categories before knowledge of
pregnancy included fewer than 5 times, 5–25 times, and more
than 25 times. For the period after knowledge of pregnancy
through the end of the pregnancy, the categories were less than
10 times, 10–50 times, and greater than 50 times. Detailed reports
on leukaemia cell cytogenetics and molecular abnormalities were
obtained for cases and included leukaemia subtype (ALL, AML)
and MLL gene translocation status (MLLþ, MLL , undeter-
mined). Data on analgesic use during pregnancy were missing for
two cases and one control. Few women reported using any type of
analgesic more than 25 times before knowledge of pregnancy or
more than 50 times after knowledge of pregnancy, which precluded
examining frequency of use. Instead, for each type of analgesic,
Table 1 Selected characteristics according to infant leukaemia status
a
Controls
(n¼323)
Acute llymphoblastic
leukaemia (n¼262)
Acute myeloid
leukaemia (n¼172)
No. (%) No. (%) OR 95% CI No. (%) OR 95% CI
Maternal characteristics
Age at index child’s birth
15–24 57 (18) 67 (26) 1.54 (0.97–2.46) 44 (26) 2.59 (1.46–4.60)
25–29 114 (35) 86 (33) 1.00 Reference 35 (20) 1.00 Reference
30–34 94 (29) 73 (28) 1.08 (0.70–1.66) 60 (35) 2.22 (1.32–3.75)
35–45 58 (18) 36 (14) 0.85 (0.51–1.43) 32 (19) 2.01 (1.10–3.67)
Education
pHigh school 91 (28) 93 (36) 1.00 Reference 53 (31) 1.00 Reference
4High school 232 (72) 169 (65) 0.68 (0.47–0.98) 119 (69) 0.80 (0.52–1.23)
Ethnicity
Caucasian 273 (85) 199 (76) 1.00 Reference 130 (76) 1.00 Reference
African American 18 (6) 11 (4) 0.67 (0.30–1.51) 7 (4) 0.88 (0.34–2.27)
Hispanic 15 (5) 29 (11) 2.60 (1.32–5.09) 24 (14) 2.51 (1.22–5.15)
Other 17 (5) 23 (9) 1.93 (0.98–3.81) 11 (6) 1.30 (0.57–2.98)
Household income
p$30000 95 (30) 99 (38) 1.51 (1.02–2.24) 54 (32) 1.01 (0.64–1.60)
$30001–$75000 145 (45) 105 (40) 1.00 Reference 82 (48) 1.00 Reference
475000 81 (25) 57 (22) 0.82 (0.53–1.27) 34 (20) 0.57 (0.34–0.96)
Pre-pregnancy BMI
Under/normal wt. 192 (59) 143 (55) 1.00 Reference 92 (53) 1.00 Reference
Overweight/obese 131 (41) 117 (45) 1.13 (0.80–1.59) 80 (47) 1.15 (0.77–1.70)
Weeks pregnant when confirmed
1–4 94 (29) 89 (34) 1.00 Reference 59 (34) 1.00 Reference
5–8 179 (55) 136 (52) 0.73 (0.50–1.07) 83 (48) 0.60 (0.39–0.95)
X9 50 (15) 37 (14) 0.71 (0.41–1.21) 30 (17) 0.86 (0.48–1.56)
Morning sickness
No 119 (37) 75 (29) 1.00 Reference 51 (30) 1.00 Reference
Yes 204 (63) 187 (71) 1.42 (0.99–2.04) 121 (70) 1.40 (0.92–2.13)
Previous fetal loss
No 240 (74) 197 (75) 1.00 Reference 133 (77) 1.00 Reference
Yes 83 (26) 65 (25) 1.11 (0.75–1.64) 39 (23) 1.00 (0.63–1.58)
Smoking during pregnancy
No 258 (80) 212 (81) 1.00 Reference 149 (87) 1.00 Reference
Yes 65 (20) 50 (19) 1.03 (0.67–1.58) 23 (13) 0.73 (0.43–1.24)
Drinking during pregnancy
No 254 (79) 219 (84) 1.00 Reference 151 (89) 1.00 Reference
Yes 69 (21) 43 (16) 0.74 (0.48–1.14) 19 (11) 0.48 (0.27–0.84)
Multivitamin use before knowledge of pregnancy
No 140 (43) 135 (52) 1.00 Reference 82 (48) 1.00 Reference
Yes 183 (57) 127 (48) 0.71 (0.51–1.00) 90 (52) 0.79 (0.53–1.17)
Child characteristics
Gender
Male 155 (48) 131 (50) 1.00 Reference 84 (49) 1.00 Reference
Female 168 (52) 131 (50) 0.95 (0.68–1.34) 88 (51) 0.99 (0.67–1.47)
Birth weight (g)
o2500 17 (5) 9 (3) 0.63 (0.26–1.49) 14 (8) 1.28 (0.58–2.84)
2500–4000 257 (80) 208 (79) 1.00 Reference 135 (78) 1.00 Reference
44000 49 (15) 45 (17) 1.22 (0.77–1.94) 23 (13) 0.87 (0.50–1.53)
Firstborn
No 205 (63) 138 (53) 1.00 Reference 109 (63) 1.00 Reference
Yes 118 (37) 124 (47) 1.45 (1.03–2.04) 63 (37) 0.88 (0.58–1.32)
Abbreviations: CI¼confidence interval; OR¼odds ratio.
aLogistic regression models adjusted for the matching factor and index child’s year of birth (continuous). Values may not
sum to the total number of cases and controls owing to missing values.
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period and a second to indicate regular use (more than 5 times
before knowledge of pregnancy or more than 10 times after
knowledge of pregnancy).
Statistical analyses were carried out using SAS version 9.2 (SAS
Institute, Cary, NC, USA). The possible association of analgesic
use and the risk of infant acute leukaemia was evaluated using
unconditional logistic regression. Odds ratios (OR) and 95%
confidence intervals (95% CI) were calculated. All models were
adjusted for the matching factor, year of birth. In addition,
maternal characteristics listed in Table 1 were evaluated as
potential confounders and included in the final regression model
if they materially altered any of the analgesic variable estimates.
All statistical tests were two-sided. Analyses were conducted
separately by leukaemia subtype (ALL, AML), and MLL status
(MLLþ, MLL ).
RESULTS
Selected characteristics of 434 infant leukaemia cases (262 ALL,
172 AML) and 323 controls are shown in Table 1. Cases and
controls were similar with respect to previous fetal loss, smoking
during pregnancy, pre-pregnancy BMI, and infant gender and
birth weight. However, compared with mothers of controls,
mothers of cases were more likely to be younger (ALL), of
Hispanic ethnicity (ALL, AML), of lower income (ALL, AML), and
to report morning sickness (ALL). Case mothers were less likely
Table 2 Association of maternal pain reliever use during pregnancy and the risk of infant leukaemia
a
Acute lymphoblastic leukaemia Acute myeloid leukaemia
N (%) N (%) OR 95% CI N (%) OR 95% CI
Aspirin
Before knowledge of pregnancy
Any use
No 287 (89.4) 236 (90.4) 1.00 Reference 158 (94.6) 1.00 Reference
Yes 34 (10.6) 25 (9.6) 1.03 0.58–1.85 9 (5.4) 0.55 0.24–1.26
Regular use
b
No 308 (96.3) 253 (96.9) 1.00 Reference 163 (97.6) 1.00 Reference
Yes 12 (3.8) 8 (3.1) 1.25 0.48–3.31 4 (2.4) 0.80 0.22–2.97
After knowledge of pregnancy
Any use
No 309 (96.3) 252 (96.6) 1.00 Reference 163 (97.0) 1.00 Reference
Yes 12 (3.7) 9 (3.5) 1.21 0.48–3.05 5 (3.0) 0.96 0.32–2.92
Regular use
b
No 314 (97.8) 255 (97.7) 1.00 Reference 166 (98.8) 1.00 Reference
Yes 7 (2.2) 6 (2.3) 1.55 0.49–4.97 2 (1.2) 0.69 0.13–3.56
Non-aspirin NSAIDS
Before knowledge of pregnancy
Any use
No 219 (68.2) 168 (64.9) 1.00 Reference 130 (77.4) 1.00 Reference
Yes 102 (31.8) 91 (35.1) 1.15 0.80–1.67 38 (22.6) 0.60 0.37–0.97
Regular use
b
No 293 (91.3) 231 (89.2) 1.00 Reference 158 (94.1) 1.00 Reference
Yes 28 (8.7) 28 (10.8) 1.41 0.78–2.57 10 (6.0) 0.68 0.29–1.59
After knowledge of pregnancy
Any use
No 292 (91.0) 232 (88.9) 1.00 Reference 158 (94.1) 1.00 Reference
Yes 29 (9.0) 29 (11.1) 1.33 0.75–2.37 10 (6.0) 0.81 0.36–1.83
Regular use
b
No 315 (98.1) 252 (96.6) 1.00 Reference 166 (98.8) 1.00 Reference
Yes 6 (1.9) 9 (3.5) 1.94 0.64–5.93 2 (1.2) 0.73 0.13–4.02
Acetaminophen
Before knowledge of pregnancy
Any use
No 113 (35.2) 92 (35.3) 1.00 Reference 76 (45.2) 1.00 Reference
Yes 208 (64.8) 169 (64.8) 1.16 0.80–1.68 92 (54.8) 0.66 0.43–1.01
Regular use
b
No 268 (83.5) 215 (82.4) 1.00 Reference 146 (86.9) 1.00 Reference
Yes 53 (16.5) 46 (17.6) 1.11 0.70–1.78 22 (13.1) 0.83 0.45–1.52
After knowledge of pregnancy
Any use
No 94 (29.4) 80 (30.7) 1.00 Reference 57 (33.9) 1.00 Reference
Yes 226 (70.6) 181 (69.4) 1.03 0.70–1.53 111 (66.1) 0.79 0.50–1.24
Regular use
b
No 247 (77.2) 191 (73.2) 1.00 Reference 137 (81.6) 1.00 Reference
Yes 73 (22.8) 70 (26.8) 1.27 0.85–1.90 31 (18.5) 0.77 0.46–1.30
Abbreviations: CI¼confidence interval; NSAIDs¼non-steroidal anti-inflammatory drugs; OR¼odds ratio.
aLogistic regression models are adjusted for maternal age (15–24,
25–29, 30–34, 35–45), race (white, black, Hispanic, other), alcohol consumption during pregnancy (yes/no), household income (o$30000, $30001–$75000, 4$75000),
and index child’s year of birth (continuous).
bRegular use of a pain reliever before and after knowledge of pregnancy is defined as X5 and X10 times, respectively.
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multivitamin use before knowledge of pregnancy (ALL), reported
alcohol consumption during pregnancy (AML), and confirmed
pregnancy before the third month (AML).
We also evaluated the distribution of cases and controls with
regard to analgesic use across selected potential confounders for
the two pregnancy periods (data not shown). Before knowledge
of pregnancy, acetaminophen was the most commonly (63%) used
analgesic, followed by non-aspirin NSAIDs (31%) and aspirin
(9%). Compared with non-regular users (p5 times), regular users
were more likely to smoke during pregnancy and less likely to have
completed education beyond high school or to report an annual
household income greater than $75000. Regular aspirin or non-
aspirin NSAID users were more likely to be Caucasian and to drink
during pregnancy, whereas regular acetaminophen users were less
likely to use multivitamins before knowledge of pregnancy,
compared with non-regular users. After knowledge of pregnancy,
acetaminophen use increased (69%), whereas the use of aspirin
and non-aspirin NSAIDs decreased (3 and 9%, respectively); only
19 case mothers and 13 control mothers used aspirin or non-
aspirin NSAIDs regularly (X10 times).
Possible associations between infant leukaemia and maternal
analgesic use, assessed both before and after knowledge of
pregnancy, are shown in Table 2. There was no association
between any use or regular use of aspirin, non-aspirin NSAIDs
or acetaminophen with infant ALL, in either pregnancy period.
However, for AML, there was a statistically significant or
borderline significant reduced risk associated with any use of
non-aspirin NSAIDs (OR¼0.60, CI: 0.37–0.97) and acetamino-
phen (OR¼0.66, CI: 0.43–1.01), respectively, but not with aspirin
(OR¼0.55, CI: 0.24–1.26); regular use of each analgesic did not
reflect further reduction in risk. These inverse associations were
observed only before knowledge of pregnancy, whereas they were
attenuated toward the null after knowledge of pregnancy.
We also examined whether associations were confined to
particular MLL groups of ALL and AML (data not shown). Among
ALL cases, 155 were MLLþ,7 7MLL , and 30 with undetermined
MLL status, whereas among AML cases there were 68 MLLþ,6 6
MLL , and 38 undetermined. For AML, the inverse association
observed for non-aspirin NSAIDs and acetaminophen was
confined to cases that did not have the MLL gene rearrangement
(OR¼0.42, CI: 0.20–0.88, and OR¼0.57, CI: 0.32–1.02, respec-
tively), whereas ALL showed no association for either MLL
subgroup.
DISCUSSION
We evaluated the association between maternal analgesic use and
the risk of infant leukaemia. Although our results suggest that
acetaminophen and non-aspirin NSAID use may be inversely
associated with infant AML when taken early in pregnancy, it
should be noted that these estimates were attenuated when
confined to regular use (X5 times). The inverse association was
confined to the subgroup containing no MLL gene rearrangement.
This subtype most closely resembles childhood AML diagnosed
after the age of 1 year, when only 5% of AML cases present with
MLL gene rearrangements (Taki et al, 1996). We found no
association between any of the analgesics studied and ALL risk.
Aspirin use had no effect on infant leukaemia risk in either
pregnancy period. However, aspirin is not recommended during
pregnancy, especially during the last trimester, although 10–30%
of women may use aspirin in the first trimester before they are
aware of their pregnancy (Werler et al, 1989; Kozer et al, 2002).
In our study, aspirin was used by 10.5% of controls and 8.5% of
cases before knowledge of pregnancy, and by 3.7% of controls and
3.3% of cases after knowledge of pregnancy.
Two out of three studies found no association between maternal
analgesic use and risk of leukaemia in children 0–14 years of age
(Wen et al, 2002; Schuz et al, 2007). In contrast, one study reported
a borderline significant two-fold increased risk of childhood ALL
associated with prescription or over-the-counter anti-inflamma-
tory drug use during pregnancy (Shaw et al, 2004). These three
studies, however, included few women who used these medications
during pregnancy. In addition, associations may have been diluted
owing to broad medication groupings and few details on specific
medications used.
Strengths and weaknesses of our study are relevant. This is the
largest infant leukaemia study to date and included availability of
MLL gene status. Identification of cases through COG provided a
nearly population-based study population, as COG institutions
see B100% of leukaemia cases aged 0–4 years (Ross et al, 1996).
We evaluated different classes of analgesics, but not their doses.
The small sample size for some subgroup analyses warrants
caution in interpretation of the relevant associations. In particular,
given the low frequency of aspirin use, especially after knowledge
of pregnancy, we had limited power to evaluate aspirin effects.
Recall bias is a concern in case–control studies, but it is unlikely
that mothers with ALL infants would recall their exposures
differently from mothers with AML. Further, the early age of onset
helped to limit the recall period. There is also some concern with
regard to selection bias. We found that use of analgesics varied by
race, income, educational attainment, and smoking or alcohol
consumption during pregnancy. Although we adjusted for
maternal race, ethnicity, income, and alcohol consumption during
pregnancy, residual confounding may remain.
In summary, this study found no significant association between
the use of over-the-counter analgesics and risk of infant leukaemia.
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